Avicanna Inc. (FRA:0NN)

Market Cap	17.45M
Revenue (ttm)	15.60M
Net Income (ttm)	-1.15M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	18,726
Open	0.1500
Previous Close	0.1600
Day's Range	0.1500 - 0.1500
52-Week Range	0.1220 - 0.2620
Beta	n/a
RSI	46.68
Earnings Date	Nov 18, 2025

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Employees: 87
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0NN

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.

Financial numbers in CAD